Dr. Dienstag has a professional interest in viral hepatitis, chronic liver disease and liver transplantation. His recent research efforts have focused on antiviral therapy for chronic viral hepatitis. He led one of 10 clinical center teams nationwide in a multiyear trial of protracted antiviral therapy for patients’ refractory to treatment for chronic hepatitis C. He was also was the leading United States academic clinical investigator in the development of lamivudine as the first approved orally administered nucleoside analog for the treatment of chronic hepatitis B.
Dr. Dienstag’s work has been published in a number of prestigious journals, including Hepatology and The New England Journal of Medicine.
Dr. Dienstag completed his medical degree at Columbia University College of Physicians and Surgeons in New York. He completed his residency at the University of Chicago Hospitals and his fellowship at Massachusetts General Hospital.
More articles on GI/endoscopy:
Bronson Pediatric Gastroenterology adds Dr. Patrick Jones
6 GI physicians in the news – Sept. 4, 2015
GI physician perspective: 3 thoughts on MOC recertification
